An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Van der Jagt, Richard H. ^{[2
]}

Kahl, Brad S. ^{[3
]}

Wood, Peter ^{[4
]}

Hawkins, Tim E. ^{[5
]}

MacDonald, David ^{[6
,7
]}

Hertzberg, Mark ^{[8
]}

Kwan, Yiu-Lam ^{[9
]}

Simpson, David ^{[10
]}

Craig, Michael ^{[11
]}

Kolibaba, Kathryn ^{[12
]}

Issa, Samar ^{[13
]}

Munteanu, Mihaela C. ^{[14
]}

Clementi, Regina ^{[15
]}

Chen, Ling ^{[16
]}

Burke, John M. ^{[17
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Ottawa, Canadian Leukemia Studies Grp, Ottawa Hosp, Ottawa, ON, Canada

[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[4] Princess Alexandra Hosp, Dept Hematol, Woolloongabba, Qld 4102, Australia

[5] Auckland Hosp, Auckland 1023, New Zealand

[6] QEII Hlth Sci, Hematol, Halifax, NS, Canada

[7] Capital Dist Hlth Author, Halifax, NS, Canada

[8] Westmead Hosp, Westmead, NSW, Australia

[9] Concord Repatriat Gen Hosp, Sydney, NSW 2139, Australia

[10] N Shore Hosp, Auckland, New Zealand

[11] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA

[12] McKesson Specialty Hlth US Oncol Res, The Woodlands, TX USA

[13] Middlemore Hosp, Haematol Lymphoma Serv, Auckland 1640, New Zealand

[14] Teva Pharmaceut Ind Ltd, Clin Operat, Oncol & Immunol, Frazer, PA USA

[15] Teva Pharmaceut Ind Ltd, Amer Reg Clin Management, Global Clin Operat, Frazer, PA USA

[16] Teva Pharmaceut Ind Ltd, Biostat, Frazer, PA USA

[17] Rocky Mt Canc Ctr, Aurora, CO USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

902

引用

页数：3

共 50 条

[1] Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study
MacDonald, David
van der Jagt, Richard
Burke, John M.
Kahl, Brad S.
Wood, Peter
Hawkins, Tim E.
Hertzberg, Mark
Kwan, Yiu-Lam
Simpson, David
Craig, Michael
Kolibaba, Kathryn S.
Issa, Samar
Clementi, Regina
Hallman, Doreen M.
Munteanu, Mihaela C.
Chen, Ling
Flinn, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Flinn, Ian W.
van der Jagt, Richard
Kahl, Brad S.
Wood, Peter
Hawkins, Tim E.
MacDonald, David
Hertzberg, Mark
Kwan, Yiu-Lam
Simpson, David
Craig, Michael
Kolibaba, Kathryn
Issa, Samar
Clementi, Regina
Hallman, Doreen M.
Munteanu, Mihaela
Chen, Ling
Burke, John M.
BLOOD, 2014, 123 (19) : 2944 - 2952
[3] Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma
Edina, Brenda Cristie
Rinaldi, Ikhwan
ACTA MEDICA INDONESIANA, 2022, 54 (02) : 316 - 323
[4] Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL)
Flinn, Ian
Van Der Jagt, Richard H. C.
Kahl, Brad S.
Wood, Peter
Hawkins, Tim E.
MacDonald, David
Hertzberg, Mark
Kwan, Yiu-Lam
Simpson, David
Craig, Michael
Kolibaba, Kathryn S.
Issa, Samar
Clementi, Regina
Hallman, Doreen M.
Munteanu, Mihaela C.
Chen, Ling
Burke, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment of primary gastrointestinal B-cell lymphoma
Aguiar Bujanda, D.
Cabrera Suarez, M. A.
Llorca Martinez, I.
Bohn Sarmiento, U.
Saura Grau, S.
Rodriguez Franco, C.
Aguiar Morales, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6] A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma
Fowler, Nathan Hale
Hiddemann, Wolfgang
Leonard, John
Rose, Esther
Ahmadl, Tahamtan
Vermeulen, Jessica
Larsen, Julie S.
Sun, Steven
Mentzer, Lisa
Wang, Shean-Shang
Yeh, Tzu-Min
Sallee, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
Candelaria, Myrna
Duenas-Gonzalez, Alfonso
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[8] Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I plus BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting
Hernandez-Rivas, Jose Angel
Zinzani, Pier Luigi
Jerkeman, Mats
Harvel, Malalatiana Be
Van Sanden, Suzy
Diels, Joris
Husain, Asad
Tapprich, Christoph
Deshpande, Sanjay
Le Gouill, Steven
Dreyling, Martin
BLOOD, 2022, 140 : 3648 - 3650
[9] A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
Fowler, Nathan Hale
Hiddemann, Wolfgang
Leonard, John
Larsen, Julie S.
Rose, Esther
Zhuang, Sen Hong
Vermeulen, Jessica
Sun, Steven
Mentzer, Lisa
Yeh, Tzu-Min
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
Linschoten, Marijke
Kamphuis, Janine A. M.
Van Rhenen, Anna
Bosman, Laurens P.
Cramer, Maarten J.
Doevendans, Pieter A.
Teske, Arco J.
Asselbergs, Folkert W.
LANCET HAEMATOLOGY, 2020, 7 (04): : E295 - E308

← 1 2 3 4 5 →